Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system
Open accessThe DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
Background: Cancer treatment with a variety of chemotherapeutic agents often is associated with delayed adverse neurological consequences. Despite their clinical importance, almost nothing is known about the basis for such effects. It is not even known whether the occurrence of delayed adverse effects requires exposure to multiple chemotherapeutic agents, the presence of both chemotherapeutic agents and the body's own response to cancer, prolonged damage to the blood-brain barrier, inflammation or other such changes. Nor are there any animal models that could enable the study of this important problem. Results: We found that clinically relevant concentrations of 5-fluorouracil (5-FU; a widely used chemotherapeutic agent) were toxic for both central nervous system (CNS) progenitor cells and non-dividing oligodendrocytes in vitro and in vivo. Short-term systemic administration of 5-FU caused both acute CNS damage and a syndrome of progressively worsening delayed damage to myelinated tracts of the CNS associated with altered transcriptional regulation in oligodendrocytes and extensive myelin pathology. Functional analysis also provided the first demonstration of delayed effects of chemotherapy on the latency of impulse conduction in the auditory system, offering the possibility of non-invasive analysis of myelin damage associated with cancer treatment. Conclusions: Our studies demonstrate that systemic treatment with a single chemotherapeutic agent, 5-FU, is sufficient to cause a syndrome of delayed CNS damage and provide the first animal model of delayed damage to white-matter tracts of individuals treated with systemic chemotherapy. Unlike that caused by local irradiation, the degeneration caused by 5-FU treatment did not correlate with either chronic inflammation or extensive vascular damage and appears to represent a new class of delayed degenerative damage in the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 CNS progenitor cells are vulnerable to clinically relevant levels of 5-FU exposure. (a) A summary of the putative relationships between the different cell types under study (for discussion of this and alternative views on lineage relationships in the CNS, see [199,200]). Pluripotent neuroepithelial stem cells (NSC) give rise to glial restricted precursor (GRP) cells and neuron restricted precursor (NRP) cells. GRP cells in turn give rise to astrocytes and oligodendrocyte-type-2 astrocyte progenitor/oligodendrocyte precursor cells (O-2A/OPCs), the ancestors of oligodendrocytes. (b,c) Primary CNS cells (b) or various cancer cell lines (c) were grown on coverslips and exposed to 5-FU for 24 h before analysis of cell viability as described in Materials and methods. 5-FU concentrations were chosen on the basis of drug concentrations reached in humans after conventional 5-FU treatment. None of the tumor lines tested were sensitive to 5-FU treatment in this dose range, whereas O-2A/OPCs, oligodendrocytes, GRP cells and human umbilical vein endothelial cells (HUVECs) were sensitive. (d,e) Exposure conditions designed to mimic the exposure levels associated with long-term infusion (d) or high-dose bolus administration (e) yielded similar results, with vulnerability of O-2A/OPCs and non-dividing oligodendrocytes to 5-FU exceeding the vulnerability of rapidly dividing cancer cells. As shown in (b,d), the vulnerability of HUVECs also exceeds the vulnerability of cancer cells. Each experiment was carried out in quadruplicate and was repeated at least twice in independent experiments. Data represent mean of survival ± s.e.m, normalized to control values.](https://figures.cochat.ai/paper-figures/1e1e4baf61204ebcbcfb8ba9503ec507/systemic-5-fluorouracil-treatment-causes-a-syndrome-of-delayed-myelin-figure-1.jpg)










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mainstay of CRC treatment, 5‐fluorouracil, has several side effects, including toxicity to both central nervous system progenitor cells and oligodendrocytes, even in the short term, limiting its long‐term clinical use [31, 32].”
From Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models (2024) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subventricular zone astrocytes are neural stem cells in the adult mammalian brain
Doetsch, F., Caillé, I., Lim, D. A., García-Verdugo, J. M., & Alvarez-Buylla, A. (1999) · Cell · doi:10.1016/s0092-8674(00)80783-7 · Cited by 3,898 · cited 20×
“In the SVZ, 5-FU exposure was associated with a 40.9 ± 2.6% decrease in numbers of BrdU+ cells on day 1, with a transient re-population of BrdU+ cells at days 7 and 14, followed by a subsequent decrease in animals examined at day 56 and 6 months after completion of treatment.”
BackgroundMethodInfluentialInflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Self-citationF4/80, a monoclonal antibody directed specifically against the mouse macrophage
Austyn, J. M., & Gordon, S. (1981) · European Journal of Immunology · doi:10.1002/eji.1830111013 · Cited by 1,579
Transient expression of doublecortin during adult neurogenesis
Brown, J. P., Couillard‐Després, S., Cooper‐Kuhn, C. M., Winkler, J., Aigner, L., & Kuhn, H. G. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10874 · Cited by 1,496
Neurogenesis in Adult Subventricular Zone
Alvarez-Buylla, A., & Garcı́a-Verdugo, J. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00629.2002 · Cited by 1,466
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Irradiation induces neural precursor-cell dysfunction
Monje, M. L., Mizumatsu, S., Fike, J. R., & Palmer, T. D. (2002) · Nature Medicine · doi:10.1038/nm749 · Cited by 1,271
Clinical Pharmacology of 5-Fluorouracil
Diasio, R. B., & Harris, B. E. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916040-00002 · Cited by 969
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968
Research works printed but not linked: 3
- Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007, 103: 303-311. 10.1007/s10549-006-9380-z. · DOI · Paper page
- Raimondi AJ, Tomita T: Advantages of 'total' resection of medulloblastoma and disadvantages of full head postoperative radiation therapy. Childs Brain. 1979, 5: 550-551.
- Cankaya H, Oner AF, Egeli E, Caksen H, Uner A, Akcay G: Auditory brainstem response in children with iron deficiency anemia. Acta Paediatr Taiwan. 2003, 44: 21-24.
Cited by
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70294-1 · Cited by 998
Prevalence, mechanisms, and management of cancer-related cognitive impairment
Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.864260 · Cited by 745
Wefel, J. S., Kesler, S. R., Noll, K. R., & Schagen, S. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21258 · Cited by 532
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer
Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010) · Cancer · doi:10.1002/cncr.25098 · Cited by 513
Oxidative Stress and Neurodegenerative Disorders
Li, J., O, W., Li, W., Jiang, Z.-G., & Ghanbari, H. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224438 · Cited by 504
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Deprez, S., Amant, F., Smeets, A., Peeters, R., Leemans, A., Van Hecke, W., Verhoeven, J. S., Christiaens, M.-R., Vandenberghe, J., Vandenbulcke, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8571 · Cited by 389
Gibson, E. M., Nagaraja, S., Ocampo, A., Tam, L. T., Wood, L. S., Pallegar, P. N., Greene, J. J., Geraghty, A. C., Goldstein, A. K., Ni, L., et al. (2019) · Cell · doi:10.1016/j.cell.2018.10.049 · Cited by 372
Hosseini, S. M. H., Hoeft, F., & Kesler, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040709 · Cited by 363
An Update on Cancer- and Chemotherapy-Related Cognitive Dysfunction: Current Status
Janelsins, M. C., Kohli, S., Mohile, S. G., Usuki, K., Ahles, T. A., & Morrow, G. R. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.03.014 · Cited by 342
Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy
Dietrich, J., Monje, M., Wefel, J., & Meyers, C. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0130 · Cited by 341
Self-citationChemotherapy and Dietary Phytochemical Agents
Sak, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/282570 · Cited by 310
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Stock, J. V. D., Smeets, A., Christiaens, M., Leemans, A., Hecke, W. V., et al. (2011) · Human Brain Mapping · doi:10.1002/hbm.21033 · Cited by 275
Cancer-treatment-induced neurotoxicity—focus on newer treatments
Stone, J. B., & DeAngelis, L. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.152 · Cited by 274
de Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., Caan, M., Douaud, G., Lavini, C., Linn, S. C., Boven, E., van Dam, F. S. A. M., et al. (2012) · Human Brain Mapping · doi:10.1002/hbm.21422 · Cited by 273
Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research
Seigers, R., & Fardell, J. E. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.09.006 · Cited by 266
Csoka, A. B., & Szyf, M. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2008.10.039 · Cited by 241
Developmental origins and emerging therapeutic opportunities for childhood cancer
Filbin, M., & Monje, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0383-9 · Cited by 223
Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis
Monje, M., & Dietrich, J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.012 · Cited by 214
Self-citationTroy+ brain stem cells cycle through quiescence and regulate their number by sensing niche occupancy
Basak, O., Krieger, T. G., Muraro, M. J., Wiebrands, K., Stange, D. E., Frias-Aldeguer, J., Rivron, N. C., van de Wetering, M., van Es, J. H., van Oudenaarden, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715911114 · Cited by 186
Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta‐analysis
DE RUITER, M. A., VAN MOURIK, R., SCHOUTEN‐VAN MEETEREN, A. Y. N., GROOTENHUIS, M. A., & OOSTERLAAN, J. (2013) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12020 · Cited by 175
Wardill, H. R., Mander, K. A., Van Sebille, Y. Z. A., Gibson, R. J., Logan, R. M., Bowen, J. M., & Sonis, S. T. (2016) · International Journal of Cancer · doi:10.1002/ijc.30252 · Cited by 174
Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases
Nguyen, L. D., & Ehrlich, B. E. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012075 · Cited by 175
Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy
Koppelmans, V., de Ruiter, M. B., van der Lijn, F., Boogerd, W., Seynaeve, C., van der Lugt, A., Vrooman, H., Niessen, W. J., Breteler, M. M. B., & Schagen, S. B. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1888-1 · Cited by 164
Risk factors for cognitive decline in children treated for brain tumors
Duffner, P. K. (2010) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2009.10.005 · Cited by 161
Chemotherapy, cognitive impairment and hippocampal toxicity
Dietrich, J., Prust, M., & Kaiser, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.016 · Cited by 169
Self-citationDoes tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?
Ganz, P. A., Bower, J. E., Kwan, L., Castellon, S. A., Silverman, D. H. S., Geist, C., Breen, E. C., Irwin, M. R., & Cole, S. W. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.07.015 · Cited by 140
Zimmer, P., Baumann, F. T., Oberste, M., Wright, P., Garthe, A., Schenk, A., Elter, T., Galvao, D. A., Bloch, W., Hübner, S. T., et al. (2016) · BioMed Research International · doi:10.1155/2016/1820954 · Cited by 125
Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats
Seigers, R., Schagen, S. B., Coppens, C. M., van der Most, P. J., van Dam, F. S. A. M., Koolhaas, J. M., & Buwalda, B. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.02.025 · Cited by 170
Chemotherapy-Related Cognitive Impairment: The Breast Cancer Experience
Myers, J. S. (2011) · Oncology nursing forum · doi:10.1188/12.onf.e31-e40 · Cited by 179
Mandelblatt, J. S., Hurria, A., McDonald, B. C., Saykin, A. J., Stern, R. A., VanMeter, J. W., McGuckin, M., Traina, T., Denduluri, N., Turner, S., et al. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.09.006 · Cited by 144
Chemotherapy-related cognitive dysfunction: current animal studies and future directions
Seigers, R., Schagen, S. B., van Tellingen, O., & Dietrich, J. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9250-3 · Cited by 159
Self-citationWigmore, P. M., Mustafa, S., ELBeltagy, M., Lyons, L., Umka, J., & Bennett, G. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6306-2_20 · Cited by 156
Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis
Mounier, N. M., Abdel-Maged, A. E.-S., Wahdan, S. A., Gad, A. M., & Azab, S. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118071 · Cited by 129
Fardell, J. E., Vardy, J. L., Shah, J. D., & Johnston, I. N. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2466-2 · Cited by 131
Koppelmans, V., de Groot, M., de Ruiter, M. B., Boogerd, W., Seynaeve, C., Vernooij, M. W., Niessen, W. J., Schagen, S. B., & Breteler, M. M. B. (2014) · Human Brain Mapping · doi:10.1002/hbm.22221 · Cited by 126
Chemotherapy-related cognitive impairment in older patients with cancer
Loh, K. P., Janelsins, M. C., Mohile, S. G., Holmes, H. M., Hsu, T., Inouye, S. K., Karuturi, M. S., Kimmick, G. G., Lichtman, S. M., Magnuson, A. M., et al. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.04.008 · Cited by 127
Neurocognitive Changes in Cancer Survivors
Correa, D. D., & Ahles, T. A. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31818d8769 · Cited by 124
Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil
ELBeltagy, M., Mustafa, S., Umka, J., Lyons, L., Salman, A., Tu, C.-Y. G., Bhalla, N., Bennett, G. W., & Wigmore, P. M. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.11.017 · Cited by 142
Neuroimmunology of Behavioral Comorbidities Associated With Cancer and Cancer Treatments
Santos, J. C., & Pyter, L. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01195 · Cited by 121
Neural correlates of chemotherapy-related cognitive impairment
Kaiser, J., Bledowski, C., & Dietrich, J. (2014) · Cortex · doi:10.1016/j.cortex.2014.01.010 · Cited by 135
Self-citationClinically Available Medicines Demonstrating Anti-Toxoplasma Activity
Neville, A. J., Zach, S. J., Wang, X., Larson, J. J., Judge, A. K., Davis, L. A., Vennerstrom, J. L., & Davis, P. H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02009-15 · Cited by 116
Briones, T. L., & Woods, J. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.07.175 · Cited by 112
Schuitema, I., Deprez, S., Van Hecke, W., Daams, M., Uyttebroeck, A., Sunaert, S., Barkhof, F., van Dulmen-den Broeder, E., van der Pal, H. J., van den Bos, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7050 · Cited by 113
Lyons, L., ElBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G., & Wigmore, P. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2122-2 · Cited by 109
Cruzado, J. A., López-Santiago, S., Martínez-Marín, V., José-Moreno, G., Custodio, A. B., & Feliu, J. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2147-x · Cited by 79
Schagen, S. B., Klein, M., Reijneveld, J. C., Brain, E. G. C., Deprez, S., Joly, F., Scherwath, A., Schrauwen, W., & Wefel, J. S. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.003 · Cited by 118
Deprez, S., Billiet, T., Sunaert, S. G., & Leemans, A. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9220-1 · Cited by 116
Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
Tom, M. C., Cahill, D. P., Buckner, J. C., Dietrich, J., Parsons, M. W., & Yu, J. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238353 · Cited by 113
Self-citationLi, T., Huang, C.-C., Ruan, P.-W., Chuang, K.-Y., Huang, K.-J., Shieh, D.-B., & Yeh, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.012 · Cited by 103
Microglia in Cancer Therapy-Related Cognitive Impairment
Gibson, E. M., & Monje, M. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.02.003 · Cited by 101
Sekeres, M. J., Bradley-Garcia, M., Martínez-Canabal, A., & Winocur, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312697 · Cited by 110
Altered small-world properties of gray matter networks in breast cancer
Hosseini, S. M. H., Koovakkattu, D., & Kesler, S. R. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-28 · Cited by 95
Standard chemoradiation for glioblastoma results in progressive brain volume loss
Prust, M. J., Jafari‐Khouzani, K., Kalpathy–Cramer, J., Polaskova, P., Batchelor, T. T., Gerstner, E. R., & Dietrich, J. (2015) · Neurology · doi:10.1212/wnl.0000000000001861 · Cited by 97
Self-citationPereira Dias, G., Hollywood, R., Bevilaqua, M. C. D. N., da Silveira da Luz, A. C. D., Hindges, R., Nardi, A. E., & Thuret, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not321 · Cited by 85
An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants
Das, A., Ranadive, N., Kinra, M., Nampoothiri, M., Arora, D. S., & Mudgal, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200221113842 · Cited by 101
Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?
Billiet, T., Emsell, L., Vandenbulcke, M., Peeters, R., Christiaens, D., Leemans, A., Van Hecke, W., Smeets, A., Amant, F., Sunaert, S., et al. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9665-8 · Cited by 81
Schroyen, G., Blommaert, J., van Weehaeghe, D., Sleurs, C., Vandenbulcke, M., Dedoncker, N., Hatse, S., Goris, A., Koole, M., Smeets, A., et al. (2021) · Cancers · doi:10.3390/cancers13164198 · Cited by 71
How chemotherapy damages the central nervous system
Meyers, C. A. (2008) · Journal of Biology · doi:10.1186/jbiol73 · Cited by 75
Abaci, H. E., Shen, Y.-I., Tan, S., & Gerecht, S. (2014) · Scientific Reports · doi:10.1038/srep04951 · Cited by 71
Cognitive impairment and chemotherapy: a brief overview
Vitali, M., Ripamonti, C. I., Roila, F., Proto, C., Signorelli, D., Imbimbo, M., Corrao, G., Brissa, A., Gallucci, R., de Braud, F., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.001 · Cited by 72
Menning, S., de Ruiter, M. B., Veltman, D. J., Boogerd, W. J., Oldenburg, H. S. A., Reneman, L., & Schagen, S. B. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9695-x · Cited by 76
Chemo brain: From discerning mechanisms to lifting the brain fog—An aging connection
Kovalchuk, A., & Kolb, B. E. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1334022 · Cited by 77
Animal models of chemotherapy-induced cognitive decline in preclinical drug development
John, J., Kinra, M., Mudgal, J., Viswanatha, G. L., & Nandakumar, K. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05977-7 · Cited by 67
Cognitive impact of cytotoxic agents in mice
Seigers, R., Loos, M., van Tellingen, O., Boogerd, W. J., Smit, A. B., & Schagen, S. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3636-9 · Cited by 73
The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory
Wigmore, P. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_235 · Cited by 66
Proposed Mechanisms for Cancer- and Treatment-Related Cognitive Changes
Merriman, J. D., Ah, D. M. V., Miaskowski, C. A., & Aouizerat, B. E. (2013) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2013.08.006 · Cited by 77
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor
Iwai, K., Nambu, T., Dairiki, R., Ohori, M., Yu, J., Burke, K. E., Gotou, M., Yamamoto, Y., Ebara, S., Shibata, S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav3660 · Cited by 73
Myers, J. S. (2009) · Clinical journal of oncology nursing · doi:10.1188/09.cjon.413-421 · Cited by 73
Dubois, M., Lapinte, N., Villier, V., Lecointre, C., Roy, V., Tonon, M., Gandolfo, P., Joly, F., Hilber, P., & Castel, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.012 · Cited by 70
Neurocognitive Function After (Chemo)-Radiotherapy for Head and Neck Cancer
Welsh, L. C., Dunlop, A., McGovern, T., Mcquaid, D., Dean, J., Gulliford, S., Bhide, S. A., Harrington, K. J., Nutting, C. M., & Newbold, K. L. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.06.014 · Cited by 59
Radiation-induced brain injury: low-hanging fruit for neuroregeneration
Burns, T. C., Awad, A. J., Li, M., & Grant, G. A. (2016) · Neurosurgical FOCUS · doi:10.3171/2016.2.focus161 · Cited by 59
Chemotherapy and the pediatric brain
Ikonomidou, C. (2018) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-018-0087-0 · Cited by 66
Zaleski-Larsen, L. A., & Fabi, S. G. (2016) · Dermatologic Surgery · doi:10.1097/dss.0000000000000556 · Cited by 54
Yu, H., Fei, J., Chen, X.-S., Cai, Q., Liu, H., Liu, G., & Yao, Z. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.079 · Cited by 57
Rendeiro, C., Sheriff, A., Bhattacharya, T. K., Gogola, J. V., Baxter, J. H., Chen, H., Helferich, W. G., Roy, E. J., & Rhodes, J. S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.043 · Cited by 58
Crosstalk between anticancer drugs and mitochondrial functions
Sahu, K., Langeh, U., Singh, C., & Singh, A. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100047 · Cited by 53
Effect of cancer therapy on neural stem cells: implications for cognitive function
Gibson, E. M., & Monje, M. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283571a8e · Cited by 57
Chemotherapy-induced cognitive impairments: White matter pathologies
Matsos, A., Loomes, M., Zhou, I., MacMillan, E. L., Sabel, I., Rotziokos, E., Beckwith, W., & Johnston, I. N. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.010 · Cited by 61
Effects of 5-fluorouracil chemotherapy on fatigue: Role of MCP-1
Mahoney, S. E., Davis, J. M., Murphy, E. A., McClellan, J. L., GORDON, B. L., & Pena, M. M. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.10.012 · Cited by 50
Fardell, J. E., Vardy, J. L., Logge, W., & Johnston, I. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.08.019 · Cited by 60
Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions
Onzi, G. R., D’Agustini, N., García, S. C., Guterres, S. S., Pohlmann, P. R., Rosa, D. D., & Pohlmann, A. R. (2022) · Drug Safety · doi:10.1007/s40264-022-01182-3 · Cited by 56
Arsenic-induced inhibition of hippocampal neurogenesis and its reversibility
Liu, S., Piao, F., Sun, X., Bai, L., Yan, P., Zhong, Y., Ma, N., & Sun, W. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.04.020 · Cited by 50
Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations
Cheung, Y. T., Chui, W. K., & Chan, A. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.001 · Cited by 46
Emerging antiangiogenic treatments for gliomas – efficacy and safety issues
Dietrich, J., Norden, A. D., & Wen, P. Y. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283131370 · Cited by 52
Self-citationChemotherapy Associated Central Nervous System Damage
Dietrich, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6306-2_11 · Cited by 47
Self-citationWalker, E. A., Foley, J. J., Clark-Vetri, R., & Raffa, R. B. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2310-8 · Cited by 44
Gu, W., Chen, J., Shao, R., Li, L., & Xu, Z. P. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61633 · Cited by 54
Mondie, C. M., Vandergrift, K. A., Wilson, C. L., Gulinello, M. E., & Weber, E. T. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.01.016 · Cited by 43
Murillo, L. C., Sutachan, J. J., & Albarracín, S. L. (2023) · Toxicology Reports · doi:10.1016/j.toxrep.2023.04.015 · Cited by 51
Neurobiological changes by cytotoxic agents in mice
Seigers, R., Loos, M., van Tellingen, O., Boogerd, W. J., Smit, A. B., & Schagen, S. B. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.057 · Cited by 52
Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis
Lee, H., Narayanan, S., Brown, R. A., Chen, J. T., Atkins, H. L., Freedman, M. S., & Arnold, D. L. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516650992 · Cited by 46
Sales, M. V. C., Suemoto, C. K., Apolinario, D., Serrao, V., Andrade, C. S., Conceição, D. M., Amaro, E., de Melo, B. A. R., & Riechelmann, R. P. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.09.002 · Cited by 26
MHC Mismatch Inhibits Neurogenesis and Neuron Maturation in Stem Cell Allografts
Chen, Z., Phillips, L., Gould, E., Campisi, J., Lee, S. W., Ormerod, B. K., Zwierzchoniewska, M., Martinez, O. M., & Palmer, T. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014787 · Cited by 42
Al-Oqail, M., Al-Sheddi, E. S., Al-Massarani, S., Siddiqui, M. A., Ahmad, J., Musarrat, J., Al-Khedhairy, A. A., & Farshori, N. N. (2017) · South African Journal of Botany · doi:10.1016/j.sajb.2017.05.019 · Cited by 40
Blommaert, J., Schroyen, G., Vandenbulcke, M., Radwan, A., Smeets, A., Peeters, R. R., Sleurs, C., Neven, P., Wildiers, H. P. M. W., Amant, F. C., et al. (2019) · Human Brain Mapping · doi:10.1002/hbm.24753 · Cited by 41
Craig, C. D., Monk, B. J., Farley, J. H., & Chase, D. M. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-2029-7 · Cited by 48
Systemic chemotherapy decreases brain glucose metabolism
Horky, L. L., Gerbaudo, V. H., Zaitsev, A., Plesniak, W., Hainer, J. M., Govindarajulu, U. S., Kikinis, R., & Dietrich, J. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.121 · Cited by 40
Self-citationELBeltagy, M., Mustafa, S., Umka, J., Lyons, L., Salman, A., Dormon, K., Allcock, C., Bennett, G., & Wigmore, P. M. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.05.005 · Cited by 39
Metadata
- Authors
- Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Pröschel, M., & Noble, M.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Noble, Mark
- Venue
- Journal of Biology
- Published
- 2008-04-22
- Volume
- 7
- Issue
- 4
- Pages
- 12-12
- ISSN
- 1475-4924 (ISSN-L)
- PMC
- PMC2397490
- OpenAlex
- W2152709121
- Cited by
- 316
- References
- 203
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 8 · 2023: 10 · 2022: 21 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 14 · 2016: 25 · 2015: 16 · 2014: 26 · 2013: 25 · 2012: 18
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Journal of Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute on Deafness and Other Communication Disorders (R01DC003086)
- National Institute of Neurological Disorders and Stroke (R01NS044701, NS44701)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD39702, R01HD039702)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- 5-fluorouracil, chemotherapy-induced neurotoxicity, white matter degeneration, myelin pathology, transcriptional regulation, auditory system, central nervous system
- MeSH terms
- Action Potentials, Animals, Antineoplastic Agents, Auditory Pathways, Bromodeoxyuridine, Central Nervous System, Fluorouracil, Humans, Indoles, Microscopy, Fluorescence, Myelin Sheath, Stem Cells, Tetrazolium Salts, Thiazoles, In Situ Nick-End Labeling, Cell Line, Tumor, Microscopy, Electron, Transmission, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.